Antimicrobial susceptibility pattern carriage isolates (women in labor) (N = 961) | |
Antibiotics | Resistant |
Erythromycin | 20 (20.8 %) (95 % CI: 12.7–29.0 %) |
Clindamycin | 25 (26.0 %) (95 % CI: 17.3–34.8 %) |
Antimicrobial susceptibility pattern of all 203 invasive isolates in 2019 (males and females) | |
Antibiotics | Resistant |
Erythromycin | 45 (22.2 %) (95 % CI: 16.5–27.9 %) |
Clindamycin | 30 (14.8 %) (95 % CI: 9.9–19.7 %) |
Antimicrobial susceptibility pattern of all EOGBS isolates in 2019 (N = 17) (newborn) | |
Antibiotics | Resistant |
Erythromycin | 3 (17.6 %) (95 % CI: − 0.05–35.8 %) |
Clindamycin | 1 (5.9 %) (95 % CI: − 5.3–17.1 %) |
Antimicrobial susceptibility pattern of all LOGBS isolates in 2019 (N = 9) (infants) | |
Antibiotics | Resistant |
Erythromycin | 6 (66.7 %) (95 % CI: 35.9–97.5 %) |
Clindamycin | 5 (55.6 %) (95 % CI: 23.1–88.0 %) |
Antimicrobial susceptibility pattern of isolates from the age group 18–44 in 2019 (N = 22) (males and females) | |
Antibiotics | Resistant |
Erythromycin | 4 (18.2 %) (95 % CI: 2.0–34.3 %) |
Clindamycin | 3 (13.6 %) (95 % CI: − 0.7–28.0 %) |
Antimicrobial susceptibility pattern of isolates from women in their fertile age (18–44 years) in 2019 (N = 17) | |
Antibiotics | Resistant |
Erythromycin | 2 (11.8 %) (95 % CI: − 3.6–27.1 %) |
Clindamycin | 1 (5.9 %) (95 % CI: − 5.3–17.1 %) |